Sign In
Buy CLRB
$2.60
-0.140 (-5.11%)
At Close: Jun 03, 2026
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
11:50am, Thursday, 14'th May 2026
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
07:15am, Thursday, 14'th May 2026
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM)
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
08:05am, Monday, 11'th May 2026
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for t
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
01:00pm, Thursday, 07'th May 2026
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What's Going With Cellectar Biosciences Stock On Wednesday?
09:17am, Wednesday, 06'th May 2026
Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing effort
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
09:50am, Tuesday, 05'th May 2026
Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the company announced promising results from its Phase 2b CLOVER WaM clinical trial.
83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulator
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
07:00am, Tuesday, 05'th May 2026
Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Manage
Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of CLR 125 in refractory TNBC, to determine recommended Phase 2 dose Study will evaluate tumor-specifi
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
11:42am, Wednesday, 04'th Mar 2026
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
07:15am, Wednesday, 04'th Mar 2026
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobuli
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
08:05am, Wednesday, 25'th Feb 2026
FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
Cellectar Biosciences Expands Global Intellectual Property Estate
08:05am, Tuesday, 17'th Feb 2026
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing A
Following Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom's Macroglobulinemia (WM), Expects to Su
